SureTrader SureTrader SureTrader
Home > Boards > Canadian > Computers - Software >

ProText Mobility, Inc. (TXTM)

TXTM RSS Feed
Add TXTM Price Alert      Hide Sticky   Hide Intro
Moderator: MIKEY501, kimokahu, dcsteve, knowmystuff, momentum2015, Unknowns
Search This Board:
Last Post: 1/22/2017 2:06:52 AM - Followers: 277 - Board type: Free - Posts Today: 5






PROTEXT MOBILITY, INC.

Stock Symbol: TXTM

http://www.protextm.co


http://plandaibiotech.com

https://twitter.com/protxtm
 
 

On December 31, 2016, we completed a share exchange with Plandaí Biotechnology South Africa (Pty) Ltd. in which we acquired 100% of the outstanding stock of Plandaí. As a result of this transaction, the shareholders of Plandaí became the majority owners of Protext Mobility and Plandaí elected to become the “successor issuer” for SEC reporting purposes.

Plandaí is a research company headquartered in the Mpumalanga province of South Africa, approximately an hour west of the Kruger National Park in the northeast part of the country. Plandaí has the worldwide exclusive license to develop and market pharmaceutical applications for Phytofare® extracts, including the green-tea derived Catechin Complex that has been clinical proven to be 10-times more bioavailable than generics.

Green tea catechins have demonstrated a wealth of clinical health benefits and can be found in many different nutraceutical products, especially for weight loss. In laboratory, in vitro studies, catechins have shown remarkable potential for treating viruses, bacterial infections, inflammation, preventing certain cancers, and regulating blood sugar levels. However, like many botanical extracts, green tea has notoriously low bioavailability. Meaning, very little of what is consumed makes it intact to the blood stream. Phytofare®, with its superior bioavailability, can deliver all 8 catechins to the blood stream at therapeutic levels, where they remain active for over 24 hours.

What this means is that we have the potential, for the first time, to use an all-natural extract for pharmaceutical applications.

Commencing in early 2017, we will be conducting a human clinical trial to determine the effectiveness of Phytofare® in controlling blood sugar levels in diabetics. Mauritius has the highest per-capita incidence levels of diabetes in the world. Assuming the trials results are favorable, we anticipate having a product market-ready by Q4 2017 specific for managing insulin.

Future clinical trials will involve both the Catechin Complex and a citrus-based Limonoid Complex as we pursue treatments for inflammation, viruses (including malaria), soft-tissue injuries, and capillary integrity.


 

Plandai Biotechnology South Africa (pty) Ltd, recently acquired by Protext Mobility, Inc, is publicly traded on the OTC Markets under the ticker symbol "TXTM"

The Company is actively engaged in the research and clinical testing of “bioceutical” products—all natural ingredients formulated for pharmaceutical applications and processed under pharma-grade conditions. Our initial product, Phytofare® Catechin Complex, has been clinically proven to have 10 times greater bioavailability over generic catechin extracts. Commencing early 2017, we will be conducting a human clinical trial to determine the effectiveness of Phytofare® in regulating blood sugar levels in diabetics. The trial will be conducted in the island country of Mauritius which has the highest per capita incidence of diabetes in the world. Assuming a favorable result, we anticipate having a product market ready by the end of 2017 and eventually filing for product claims with the US Food and Drug Administration.

We are majority-owned by Plandaí Biotechnology, Inc. (OTCQB: PLPL), a London-based holding company that controls over 8,000 acres of tea estate in the province of Mpumalanga, South Africa, and owns a 100,000 square foot manufacturing facility that produces Phytofare®.









PROTEXT MOBILITY CLOSES ACQUISTION OF PLANDAI BIOTECHNOLOGY WHOLLY OWNED SUBSIDIARY (PLPL-SA) Boca Raton, FL – January 11th, 2016 - Protext Mobility Inc. (OTCPINK: TXTM) announced that it has completed the acquisition of Plandaí Biotechnology South Africa (PTY) LTD “Plandaí SA”, a wholly owned subsidiary of Plandaí Biotechnology, Inc., publicly traded under the ticker (PLPL). Plandaí SA is a biotechnology firm engaged in the research and development of botanical extracts, such as green tea, aimed at treating metabolic disorders, including diabetes. The parent company of Plandaí SA, Plandaí Biotechnology, Inc., is the culmination of over 10 years of research and development in the field of plant extracts with principle holdings including raw materials processing, infrastructure, production facilities, farms and land totaling 7500 acres in the province of Mpumalanga, South Africa. Plandaí SA was established in 2014 by parent company, Plandaí Biotechnology, Inc. to provide a platform for expanding the research of Plandaí’s proprietary Phytofare® extracts into pharmaceutical applications. Phytofare® has been clinically proven in studies to provide ten times greater bioavailability, which is the ability of the body to absorb the nutrients, over generic plant extracts. The first product brought to market, Phytofare® catechin complex, is derived from green tea and contains all eight catechins in a highly absorbable biocompatible structure. Where the parent company, Plandaí Biotechnology, focuses on selling Phytofare® as an ingredient to manufacturers in the nutraceutical industry, Plandaí SA will target the pharmaceutical market with a finished product. Plandaí SA has the exclusive license and rights to develop, manufacture, and sell all current and future Phytofare® extracts for the pharmaceutical market worldwide. The first targeted product will focus on treating diabetes by regulating blood sugar levels with an expectation of being market ready in the latter half of 2017. David Lewis, Director of Protext Mobility, commented, “We’re pleased to announce this share exchange with Plandaí SA and we’re confident that this transaction will create exciting new opportunities for the company. Plandaí has a proven track record for delivering high-quality, science-based botanical ingredients that fit perfectly into the bio-pharmaceutical space. With the first human clinical trial set to commence in the first quarter of 2017, we anticipate great things in the coming months.” The Company is also pleased to announce the appointment of Mr. Roger Duffield to the role of Chief Executive Officer and Chairman of the Board. Mr Duffield is a seasoned executive, responsible for the massive undertaking and successful development of the 7500 acre Senteeko Estate. Mr.Duffield, is a hands on CEO, currently in South Africa, overseeing the 100,000 square foot factory, and preparing for the upcoming human clinical trial being conducted by Plandai SA. 
 

Plandai Biotechnology South Africa

Plandaí Biotechnology South Africa (Pty) Ltd, recently acquired by Protext Mobility, Inc.(OTCPINK: TXTM) is a South Africa-based research company focusing on the development of pharmaceutical applications for botanical drugs.

Plandaí South Africa has the worldwide exclusive license to develop Phytofare® in botanical drug applications. Phytofare® is a highly bioavailable extract produced from live green tea leaves that has been clinically proven in double-blind human trials to have ten-times greater bioavailability over generic extract. What this means is that Phytofare® can deliver a therapeutic level of catechins to the system where they remain active for over 24 hours. The Company plans to commence human clinical trials to determine the effectiveness of using Phytofare® catechin complex in regulating insulin levels in Type II Diabetes patients.

Diabetes is now the leading cause of death in South Africa and the rates are only climbing through much of sub-Sahara Africa and the developing world where fat-rich foods have supplanted traditional diets. There is a strong body of scientific research that points to the effectiveness of green tea catechins in managing obesity, high blood pressure, diabetes and other diet-related diseases. Data from in vitro and in vivo studies suggest that green tea catechins, in particularly EGCG, exert anti-obesity effects via several mechanisms including inhibition of adipocyte differentiation and proliferation, reduction of fat absorption, and the reduction in fat mass, tricylglycerides, free fatty acids and total cholesterol. The majority of human intervention studies investigating glucose homeostasis further demonstrate improved glucose levels in response to green tea catechins. Human studies have shown anti-obesity, anti-diabetic and cardio-protective effects of green tea catechins (1).

However, as we all know, like many botanical ingredients green tea is poorly absorbed into the blood stream, rendering it an ineffective primary control therapy. Phytofare®, on the other hand, which has ten-times greater absorption, may very well provide an inexpensive, all-natural solution to these diseases. Our clinical trial is designed to build on this prior research and show the benefits of Phytofare® in managing glucose levels, with a short-term goal of having a consumer-ready capsule product by Q4, 2017.

Worldwide as of 2015, 415 million people had diabetes, with the number growing to over 642 million people in 2016, with Type II Diabetes making up about 90% of the cases. In 2014, the IDF estimated that diabetes resulted in 4.9 million annual deaths.

1. F. Thielecke, M. Boschmann / Phytochemistry (2009) “The potential role of green tea catechins in the prevention of the metabolic syndrome” ?
 

Roger Duffield - President & CEO

Roger Duffield has a significant background in the development and management of start-ups, private and public companies, especially in the United States, Europe and South Africa. His previous contributions in the United States public sector include Klinair Technologies Inc. and Rhombic Inc. relating to energy and hydrocarbon technologies. Through his extensive involvement with research and development programs with a number of academic institutions, including Penn State, University of Southern California, University of Washington, and the University of Limerick, Ireland, he was awarded two honorary Russian doctorates in Natural Sciences from the University of Moscow and Novosibirsk. In 2001 the Foundation for International Services, California recognized a degree in BSc. Chemical Engineering.

In 2001 he co-founded Global Energy Solutions Corporation Limited, Dublin, Ireland, recently acquired by Plandaí Biotechnology, Inc., and in 2003, the USA-based Research Company, CRS Technologies Inc. Mr. Duffield now heads this group of companies specializing, through private and public investment in the farming and recovery of highly valuable botanical extracts with unique characteristics.'


Contact Details

9 Palm Street
White River 1240
Mpumalanga
South Africa

 P: +1 (435) 881 3611
 E: [email protected]

  •  
     
RESURRECTED FROM A LONG REST!
 
 

 


 

 

American Stock Transfer & Trust Company
Transfer Agent
6201 15th Avenue
Brooklyn, NY 11219
800-937-5449
http://www.amstock.com
 


  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
TXTM
Current Price
Volume:
Bid Ask Day's Range
SureTrader
TXTM News: Current Report Filing (8-k) 01/19/2017 11:32:53 AM
TXTM News: Plandai Biotechnology Announces Share Exchange Between Protext Mobility and Plandai's South Africa Subsidiary 01/10/2017 07:43:54 AM
TXTM News: Current Report Filing (8-k) 12/23/2016 09:05:49 AM
TXTM News: Current Report Filing (8-k) 12/13/2016 11:35:43 AM
TXTM News: Friendable Inc. (OTC Pink: FDBL), Fan Pass Live “Coming January 2017.” Exclusive, Live, Uncut, Uncensored Celebrity Content 12/13/2016 07:00:00 AM
PostSubject
#17683  Sticky Note Huge Feb 2017 Marijuana Legalization in South Africa stervc 01/20/17 04:26:18 PM
#16819  Sticky Note *** 1-11-2017 TXTM ACQUISITION/MERGER NEWS OUT *** MIKEY501 01/11/17 12:40:56 PM
#15818  Sticky Note BIG DD TXTM ACQUISTION polochinos 12/23/16 01:10:07 PM
#12849  Sticky Note Protext Mobility Inc (TXTM) Launches New Website and Carjockey2 12/12/16 02:18:20 PM
#11243  Sticky Note NEWS 12/7: halt debt conversions for a period dcsteve 12/09/16 01:59:07 PM
#17746   Thanks DD_d fink 01/22/17 02:06:52 AM
#17745   TXTM...WILL FLY TO PENNIES..THE MEGA-MERGER IS AWSOME, THE halbroke1 01/22/17 01:20:21 AM
#17744   Plandaí, entered into a 49-year notarial lease on Queensdweller 01/22/17 01:15:22 AM
#17743   Fink and ALL- With $TXTM DD_dempsey 01/22/17 12:58:45 AM
#17742   Stervc, good to see you on this. fink 01/22/17 12:10:29 AM
#17741   agreed and not just South Africa with TXTM mymonies 01/21/17 11:52:32 PM
#17740   Sterling ,the DD from the 8-k on TXTM balamidas 01/21/17 11:48:00 PM
#17739   Great post. Should get the attention here we stockpicker1 01/21/17 11:32:57 PM
#17738   Sunkist ... Wow! That's big... we are def. Digging For Pennies 01/21/17 11:04:00 PM
#17737   Thanks DD_dempsey and Stervc for in-depth analysis on Gan 01/21/17 08:05:03 PM
#17736   Get this stickied please! Remarkable DD well done ! PharmD18 01/21/17 07:45:55 PM
#17735   Are we getting a new ticker symbol as whynot1790 01/21/17 06:57:06 PM
#17734   $TXTM At least 800M shares traded during Thursday trading.jeff 01/21/17 05:44:12 PM
#17733   And apparently so will South Africans....on 2/1/17 DD_dempsey 01/21/17 05:35:22 PM
#17732   Accumulation is high @ TXTM Liquid1974 01/21/17 05:30:04 PM
#17731   Artist and .ALL- there is no doubt now DD_dempsey 01/21/17 05:21:09 PM
#17730   I noticed the fifth decimal 500k trades too. Liquid1974 01/21/17 05:07:09 PM
#17729   I think you can probably get 7's early flemdog33 01/21/17 05:04:20 PM
#17728   WOW...Thanks stervc but I really wished that you Carjockey2 01/21/17 04:35:56 PM
#17727   THIS MJ STOCK IS GONNA RUN FOR DAYS/WEEKS/MONTHS! Jobrano 01/21/17 04:32:05 PM
#17726   I am posting TXTM 1 year chart look ARTIST 01/21/17 04:26:39 PM
#17725   RBNEWS, with these TXTM thoughts... stervc 01/21/17 04:15:07 PM
#17724   Thank you for all the DD stervc and flemdog33 01/21/17 04:10:00 PM
#17723   JPS02, here with TXTM... stervc 01/21/17 03:54:32 PM
#17722   TXTM/PLPL, Sunkist, USDA, & CDXC:NASDAQ Connection stervc 01/21/17 03:44:39 PM
#17721   solid DD stervc ARTIST 01/21/17 03:34:25 PM
#17720   Hi Stervc, Agree. Know your DD well. RBNEWS 01/21/17 03:22:35 PM
#17719   Looking sideways trade .0006-.0008.... Txtm Liquid1974 01/21/17 03:18:52 PM
#17718   On December 31, 2016, we completed a share JPS02 01/21/17 03:17:02 PM
#17717   Awesome dd! $$$ Jobrano 01/21/17 01:29:39 PM
#17716   Looking forward to this week! Full 5 days stockpicker1 01/21/17 01:02:22 PM
#17715   TXTM GOING TO THE MOON NEXT WEEK $$$$$...WATCH halbroke1 01/21/17 12:52:16 PM
#17714   I was thinking the same.. TXTM Liquid1974 01/21/17 12:10:59 PM
#17713   Key TXTM & PLPL Connecting Variables stervc 01/21/17 12:09:12 PM
#17712   mymonies, with these significant TXTM thoughts… stervc 01/21/17 12:05:24 PM
#17711   good to see you here DD dempsey, always mymonies 01/21/17 10:32:31 AM
#17710   Hope to get some 7's or 8's before Jobrano 01/21/17 10:22:50 AM
#17709   Great info guys. The sky is the limit whynot1790 01/21/17 10:19:07 AM
#17708   Great dd.. Liquid1974 01/21/17 09:10:08 AM
#17707   Research and Development - Citrus JPS02 01/21/17 09:00:33 AM
#17706   Medicines Control Council wishes to clarify the current Queensdweller 01/21/17 08:56:38 AM
#17705   This is really bigger then I thought $$$. Jobrano 01/21/17 04:21:18 AM
#17704   $TXTM now presents itself as a legal MM DD_dempsey 01/21/17 03:46:33 AM
#17703   Stervc with this HUGE validation of TXTM/PLPL Marijuana connection DD_dempsey 01/21/17 03:36:55 AM
#17702   nice post....MMJ already approved in South Africa mymonies 01/21/17 01:25:54 AM
#17701   yes i think they want to have a mymonies 01/21/17 01:20:51 AM
#17700   yes,very exciting, mostly in the 6s and 7s....strong base mymonies 01/21/17 01:18:35 AM
#17699   as well as all the other stock you mymonies 01/21/17 01:17:06 AM
#17698   yes it truly is my friend mymonies 01/21/17 01:09:28 AM
#17697   hello Bernardo 75 from Bavaria greetings from Canada, mymonies 01/21/17 01:07:58 AM
PostSubject